The Ultimate Guide To Digitizing Cell And Gene Therapy Manufacturing

Cell and gene therapeutics (CGT) continue to experience exponential growth and are at the very center of healthcare innovation – having already contributed to some of the most significant disruptions in the pharmaceutical and biotech industries. Private equity and venture capital investment in CGT companies continues to dramatically outpace the rest of the life sciences industry. With all this growth, the industry is now facing one of its biggest challenges – a significant shortage of manufacturing capacity. Here we explore scaling up techniques for cell and gene manufacturing, digitalizing operations, compliance through connected operations, and establishing cGMP.